Boehringer Ingelheim, MorphoSys Expand Antibody-development Collaboration | GenomeWeb

NEW YORK, March 18 (GenomeWeb News) - Boehringer Ingelheim has obtained from MorphoSys the option to exclusively license several therapeutic antibodies being co-developed by the firms under a previous agreement with the two companies, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.